Wide-ranging studies of genetic aberrations have identified recurrent genomic abnormalities as potential driving factors underlying a variety of cancers and other diseases.
At PacificDx Testing Services, we support many of these leading-edge molecular and non-molecular technologies for diagnostic biomarker interrogation, drug selection targeting, and therapeutic monitoring. These include but are not limited to Next Generation Sequencing (NGS), Enzyme-linked immunosorbent assay (ELISA), Flow Cytometry, and Real-Time PCR and Immunohistochemistry (IHC). If you don’t see what you are looking for, please ask — we are a premier high-complexity molecular laboratory with advanced capabilities.
Please visit our companion diagnostics company, ResearchDx, to learn how our IVD and biopharma development services can simplify delivery of your FDA-approved companion diagnostics on time.